Tesamorelin targets one specific problem — visceral fat around the organs — and the clinical data on it is narrower and more specific than most peptide marketing lets on. This guide breaks down who it actually fits, what the trial numbers say, and where it falls short.
- Tesamorelin visceral fat reduction averages roughly 15-18% over 26 weeks in FDA trial data — Consider with clinician oversight.
- Tesamorelin does not drive weight loss like semaglutide or tirzepatide; it targets visceral fat specifically, not the scale.
- Standard dosing is 2mg subcutaneous daily; stopping the drug reverses visceral fat gains within roughly six months.
- Unregulated research-peptide sellers skip baseline labs and IGF-1 monitoring entirely — Skip those sources.
Why this matters
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, marketed as Egrifta SV, and it was approved in 2010 specifically for reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy. That's a narrow FDA indication, and it matters because a lot of the interest in tesamorelin now comes from people outside that population who've heard it described as a general fat-loss peptide.
It isn't. Trials behind the approval showed meaningful visceral adipose tissue (VAT) reduction with only modest change in total body weight or BMI. If you're picturing something like semaglutide or tirzepatide but for belly fat specifically, that's closer to the truth — and closer to understanding why clinician oversight matters here in 2026 as much as it did in 2010.
Rebody Health's growth hormone therapy program works with adults navigating this exact GH-axis category — sermorelin, tesamorelin-adjacent GHRH peptides, and related longevity protocols — under licensed clinician review rather than unsupervised sourcing.
Who this is for
This is for adults who've already addressed diet and training and still carry disproportionate abdominal visceral fat — often flagged on a DEXA scan or estimated from waist circumference — and who want a medically supervised option rather than a research-chemical purchase off a peptide forum. It fits people already engaged with hormone or longevity care, sometimes stacked with testosterone therapy, who understand tesamorelin is a targeted tool, not a weight-loss drug.
What to look for in tesamorelin for visceral fat reduction
Confirmed visceral fat, not just extra weight
Tesamorelin's trial data is about VAT specifically, measured by CT or MRI in the pivotal studies — not subcutaneous fat or overall body weight. If your main goal is dropping 30 pounds, this isn't the right tool; a GLP-1 protocol targets that differently. If the goal is the visceral fat driving metabolic risk, tesamorelin has a real evidence base behind it.
Baseline labs before starting
IGF-1, fasting glucose, and A1c should be checked before dosing starts. Tesamorelin raises IGF-1 as part of its mechanism, and the FDA label flags glucose intolerance as a monitored risk, so a clinician needs a starting point to compare against at 12 and 26 weeks.
Licensed clinician oversight, not a peptide forum
Tesamorelin is a prescription drug in the US, not a research chemical. A legitimate pathway means a licensed clinician reviewing your history, active malignancy screening, and pituitary tumor history before writing anything — that's a hard stop for people who can't clear that screen.
A realistic 26-week timeline
The trial data that supports tesamorelin's approval measured outcomes at 26 weeks, not 26 days. Anyone expecting visible visceral fat change inside a month is working from the wrong reference point.
Side-effect monitoring built in
Injection-site reactions, joint pain (arthralgia), fluid retention, and paresthesia show up in the label's adverse-event data. None of these are rare footnotes — they're common enough that follow-up visits should be scheduled, not optional.
Compatibility with what you're already doing
If you're on testosterone therapy already, tesamorelin's GH-axis mechanism is a different pathway than androgen receptor signaling, and some adults run both under supervision. That's a stacking decision for a clinician, not a self-directed one.
Top approaches, ranked
Tesamorelin monotherapy — the clinical-standard pick
Standard dosing is 2mg subcutaneous daily, and this is the protocol behind the 2010 approval data: roughly 15-18% VAT reduction at 26 weeks versus a small increase in the placebo arm. Weight and BMI barely moved in the same trials, which is the tradeoff to understand going in. This is the pick if visceral fat, not body weight, is the actual target and you want the option with the most trial data behind it. Consider — with baseline labs and a 26-week commitment, not a quick trial run.
A related mechanism worth knowing: sermorelin injections work on a similar GHRH pathway but are typically used for broader growth hormone deficiency rather than the visceral-fat-specific indication tesamorelin carries.
Tesamorelin stacked with TRT — for men already on hormone therapy
Some adults already running testosterone therapy for body composition goals add tesamorelin under clinician supervision, since the two mechanisms don't overlap directly. The tradeoff: more moving pieces to monitor, more lab draws, and a clinician who needs visibility into both protocols at once. If you're already deep into a TRT for weight loss and body composition protocol and visceral fat specifically hasn't budged, this is worth a clinician conversation. Consider — only with a single provider managing both.
Sermorelin as a lower-intensity alternative
Sermorelin is a shorter-acting GHRH analog, generally positioned for broader growth hormone support rather than the visceral-fat-specific data tesamorelin has behind it. It's a reasonable starting point for adults who want GH-axis support without committing to tesamorelin's narrower, more clinically-documented use case. Consider — if the goal is general GH support rather than targeted visceral fat reduction specifically.
Unsupervised "research peptide" tesamorelin — the one to skip
Tesamorelin sold as a research chemical, without a prescription, without baseline IGF-1 or glucose labs, and without follow-up monitoring is a real pattern in this category in 2026. No dosing verification, no purity guarantee, no clinician catching a glucose spike or a contraindication. Skip — every problem this approach avoids is a problem the trial data says to watch for.
What to avoid
- Expecting scale weight to move. The trial data behind tesamorelin's approval shows visceral fat reduction with minimal total weight change — if the number on the scale is the goal, this isn't the tool.
- Skipping the 26-week window. Judging tesamorelin at 8 or 12 weeks against data measured at 26 weeks sets up a false disappointment.
- Sourcing it without a prescription. Research-chemical tesamorelin bypasses every monitoring step the label calls for, including IGF-1 and glucose checks.
Verdict comparison
| Approach | Best for | Visceral fat effect | Weight change | Verdict |
|---|---|---|---|---|
| Tesamorelin monotherapy | Confirmed visceral fat, GH-axis candidates | ~15-18% at 26 weeks | Minimal | Consider |
| Tesamorelin + TRT stack | Men already on testosterone therapy | Similar to monotherapy | Varies with TRT | Consider |
| Sermorelin instead | Broader GH support, not visceral-fat-specific | Less trial-documented for VAT | Minimal | Consider |
| Unsupervised research peptide | No one, structurally | Unverified | Unverified | Skip |
FAQ
What is tesamorelin used for?
Tesamorelin is a GHRH analog approved in 2010 to reduce excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It's a targeted visceral-fat drug, not a general weight-loss medication.
Is tesamorelin FDA-approved for everyone with visceral fat?
No, the FDA approval covers HIV-associated lipodystrophy specifically. Use outside that population is off-label and needs clinician review of the actual evidence and your individual risk factors.
How much visceral fat does tesamorelin actually reduce?
Trial data behind the approval showed roughly 15-18% visceral adipose tissue reduction over 26 weeks compared with a small increase in the placebo group. Results at shorter timelines are less established.
Does tesamorelin cause weight loss like semaglutide or tirzepatide?
No. Tesamorelin trials showed minimal change in total body weight or BMI even as visceral fat dropped, which is a different mechanism and outcome than GLP-1 medications.
What are the main side effects of tesamorelin?
Injection-site reactions, joint pain, fluid retention, and paresthesia are the most commonly reported effects in label data. Glucose intolerance is monitored because tesamorelin raises IGF-1 as part of its mechanism.
How is tesamorelin different from sermorelin?
Both are GHRH analogs, but tesamorelin has a specific FDA indication and trial data for visceral fat reduction, while sermorelin is generally used for broader growth hormone support. They aren't interchangeable for the same goal.
Can you stack tesamorelin with TRT?
Some adults on testosterone therapy add tesamorelin under a single clinician's supervision since the mechanisms don't overlap directly. It requires more lab monitoring, not less, so self-directed stacking isn't the safe version of this.
What happens if you stop taking tesamorelin?
Visceral fat tends to return toward baseline within roughly six months of discontinuation, based on maintenance-phase trial data. Tesamorelin doesn't produce a permanent structural change on its own.
One last thing
The detail most people miss: tesamorelin's own maintenance trials showed visceral fat creeping back toward baseline within about six months of stopping. That's not a flaw unique to tesamorelin — it's true of most GH-axis interventions — but it means the real decision isn't whether to start, it's whether you're prepared to treat this as an ongoing protocol with lab check-ins, not a one-time 26-week fix.